Advanced Therapies Manufacturing Strategy Digital

Assess the current manufacturing landscape in the context of the COVID-19 pandemic. What are the short and long term implications for advanced therapeutics development?

July 14 - 15, 2020 | Virtual Event

View Program

Vendor Registration

Free End User Registration

Meet the Speakers

View the event program for additional information on speakers, sessions, networking activities, and more!

Peter Marks MD, PhD
Director, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)

Steven Goodman
Head of Drug Product Manufacturing
Bluebird Bio

Mark Plavsic
Chief Technology Officer and Head of Nonclinical Development
LYSOGENE

Kelvin H. Lee
Institute Director
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

Craig Malzahn
Head of Technical Operations
REGENXBIO Inc.

Rick Silva PhD
Executive Director, Clinical, Translation and Industry Collaborations
Texas A&M Health Science Center

Vlad Hogenhuis
Chief Operating Officer (fmr.)
Ultragenyx

Michael Lehmicke
Director, Science and Industry Affairs
Alliance for Regenerative Medicine

QUESTIONS?
Contact us: 1-800-882-8684
Email: enquiry@iqpc.com